INR:9310. danske spil oddset regler 『Pharmaceutical Headlines』CD147 antibody clinical trial data released, epidemic makes disinfectant popular Chine ...

Tmall's shopping list for the pharmaceutical platform on Double Eleven! The transaction volume exceeded 100 million in just 2 minutes ...

INR:0330. ace 2 three plus 4 Novo Nordisk's Fiasp is approved in Canada for use in pediatric patients aged ≥ 2 years! After much anticipation, this new breas ...

live cricket score india and australia Innovent Biologics Obtains Exclusive Rights to Two Cell Immunotherapy Products in Mainland China, Hong Kong and Macau Novo Nordisk Q1 2020: China grew 13%, ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.

Zealand Pharma's GLP-2 drug candidate fails to gain FDA approval due to request for additional trial to confirm efficacy and safety.